ALKBH5通过靶向AXIN2驱动免疫抑制促进结直肠癌并可作为增强免疫治疗的靶点
研究在205例人样本中评估ALKBH5的临床意义,并在同种移植瘤、CD34+人源化小鼠和Alkbh5敲入小鼠中研究其功能。高ALKBH5表达预示结直肠癌预后不良,ALKBH5通过AXIN2降解激活Wnt/β-catenin诱导DKK1,招募髓源性抑制细胞驱动免疫抑制。载ALKBH5-siRNA的囊泡样纳米颗粒或抗DKK1可增强抗PD1抑制结直肠癌生长的效果。
要点
- 高ALKBH5表达预示结直肠癌预后不良
- ALKBH5通过AXIN2降解激活Wnt/β-catenin诱导DKK1招募髓源性抑制细胞
- 载ALKBH5-siRNA纳米颗粒或抗DKK1增强抗PD1抑制结直肠癌生长
核心结论
- 本研究在结直肠癌中鉴定出ALKBH5-N6-甲基腺苷-AXIN2-Wnt-DKK1轴,该轴驱动免疫抑制促进肿瘤发生。
- 靶向ALKBH5是使结直肠癌对免疫治疗增敏的有前景策略。
研究设计与样本
- 在人样本(n=205)中评估ALKBH5的临床意义。
- 在同种移植瘤、CD34+人源化小鼠和Alkbh5敲入小鼠中研究ALKBH5功能。
- 采用流式细胞术、免疫荧光和功能研究测定免疫变化。
- 采用甲基化RNA免疫沉淀测序和RNA测序鉴定ALKBH5靶点。
- 构建囊泡样纳米颗粒包裹的ALKBH5小干扰RNA用于体内靶向ALKBH5。
主要发现
- 高ALKBH5表达预示结直肠癌预后不良。
- ALKBH5诱导髓源性抑制细胞积累,减少自然杀伤细胞和细胞毒性CD8+ T细胞,促进结直肠肿瘤发生。
- AXIN2被鉴定为ALKBH5的靶点,ALKBH5结合并去甲基化AXIN2信使RNA,导致其从N6-甲基腺苷阅读蛋白IGF2BP1解离并降解,引起Wnt/β-catenin过度激活。
- ALKBH5诱导包括DKK1在内的Wnt/β-catenin靶点,ALKBH5诱导的DKK1招募髓源性抑制细胞驱动免疫抑制,该效应在体外和体内被抗DKK1消除。
- 囊泡样纳米颗粒包裹的ALKBH5小干扰RNA或抗DKK1增强抗PD1抑制结直肠癌生长的效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Immune checkpoint blockade therapy benefits only a small subset of patients with colorectal cancer (CRC), and identification of CRC-intrinsic events modulating immune checkpoint blockade efficacy is an unmet need. We found that AlkB homolog 5 (ALKBH5), an RNA N6-methyladenosine eraser, drives immunosuppression and is a molecular target to boost immune checkpoint blockade therapy in CRC. METHODS: Clinical significance of ALKBH5 was evaluated in human samples (n = 205). Function of ALKBH5 was investigated in allografts, CD34+ humanized mice, and Alkbh5 knockin mice. Immunity change was determined by means of flow cytometry, immunofluorescence, and functional investigation. Methylated RNA immunoprecipitation sequencing and RNA sequencing were used to identify ALKBH5 targets. Vesicle-like nanoparticle-encapsulated ALKBH5-small interfering RNA was constructed for targeting ALKBH5 in vivo. RESULTS: High ALKBH5 expression predicts poor prognosis in CRC. ALKBH5 induced myeloid-derived suppressor cell accumulation but reduced natural killer cells and cytotoxic CD8+ T cells to induce colorectal tumorigenesis in allografts, CD34+ humanized mice, and intestine-specific Alkbh5 knockin mice. Mechanistically, AXIN2, a Wnt suppressor, was identified as a target of ALKBH5. ALKBH5 binds and demethylates AXIN2 messenger RNA, which caused its dissociation from N6-methyladenosine reader IGF2BP1 and degradation, resulting in hyperactivated Wnt/β-catenin. Subsequently, Wnt/β-catenin targets, including Dickkopf-related protein 1 (DKK1) were induced by ALKBH5. ALKBH5-induced DKK1 recruited myeloid-derived suppressor cells to drive immunosuppression in CRC, and this effect was abolished by anti-DKK1 in vitro and in vivo. Finally, vesicle-like nanoparticle-encapsulated ALKBH5-small interfering RNA, or anti-DKK1 potentiated anti-PD1 treatment in suppressing CRC growth by enhancing antitumor immunity. CONCLUSIONS: This study identified an ALKBH5-N6-methyladenosine-AXIN2-Wnt-DKK1 axis in CRC, which drives immune suppression to facilitate tumorigenesis. Targeting of ALKBH5 is a promising strategy for sensitizing CRC to immunotherapy.
引用
- Zhai J, Chen H, Wong CC, et al. ALKBH5 Drives Immune Suppression Via Targeting AXIN2 to Promote Colorectal Cancer and Is a Target for Boosting Immunotherapy. Gastroenterology. 2023. PMID: 37169182. doi:10.1053/j.gastro.2023.04.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。